Navigation Links
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Date:11/26/2008

fective in treating indolent NHL. Although approved by the FDA in 2002, its potential has not been fully realized. We are proud to partner with Cell Therapeutics, which over the past year has made great headway toward removing many of the obstacles that have kept this important drug from patients that could benefit from it. There are approximately one thousand patients currently receiving ZEVALIN treatments for refractory indolent NHL, generating approximately $15 million in annual sales. If approved for first line consolidation therapy in indolent NHL, we estimate that an additional 18,000 patients per year would be eligible to receive ZEVALIN in this setting. We assembled an experienced sales force, comprised of individuals with established track records of success, to launch our recently approved drug FUSILEV. ZEVALIN represents a complementary product that our sales force can provide to their accounts."

"This partnership is especially important as we hope to move toward use of ZEVALIN in first-line consolidation treatment of indolent NHL patients, which would significantly expand the available patient population," said James A. Bianco, M.D., CEO of Cell Therapeutics. "This partnership will enable CTI to deploy a larger combined sales and marketing team to accelerate top-line product revenues in the near-term and reduce our costs to develop ZEVALIN for new growth opportunities, resulting in an increase in CTI's bottom-line overall. Spectrum has a wealth of experience in the field of oncology, including the sales and marketing leadership that oversaw the successful launch of Abraxane(R) and Xeloda(R). We believe the Spectrum partnership allows us to better serve patients and capitalize on the growing recognition of ZEVALIN's effectiveness in patients with indolent NHL, while at the same time provide a significant return on investment for our shareholders."

Under terms of the agreement, upon the closing o
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.; Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
2. Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities
3. "Brave New Reality" Provides a Wide Spectrum of High Tech News and Easy Science.
4. Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale
5. Energetiqs Laser-Driven Light Source Technology Enables Continuous Spectrum Light Sources, from Visible to Deep Ultraviolet
6. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
7. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Global Experts Explore Entire Spectrum of Aids Vaccine Development
10. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/15/2014)... SYDNEY , Sept. 15, 2014 ... focused on revolutionizing the treatment of cancer through ... cancer cells, announced that, together with the Asbestos ... 2014 Cancer Institute New South Wales (NSW) Premier,s ... other four recipients are the hospitals that will ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... France, April 23 , - ... Essilor International, the world leader in ophthalmic optics, today,announced ... 31, 2009, representing a reported 10.3% increase on the first ... the period. , Despite contracting demand ...
... RICHMOND, Calif., April 22 Sangamo BioSciences, Inc. (Nasdaq: ... will release its first quarter 2009 financial results on ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ...
... to Discuss Results to Be Held at 9:00 A.M. - ... VPHM ) first quarter financial results for 2009 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 3ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2
(Date:9/15/2014)... on Earth for the first 500 million years after ... present day, complete with oceans, continents and active crustal ... eon, called the Hadean, has gained substantial new support ... formed more than 4 billion years ago with those ... a possible geological analog for early Earth. , The ...
(Date:9/15/2014)... are hallmarks of the cheetah: The big predator is the ... mph in just a few seconds. As it ramps up ... bounding until it reaches a full gallop. , Now MIT ... implemented in a robotic cheetah a sleek, four-legged assemblage ... much as its feline counterpart. The team recently took the ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Run, cheetah, run 2Run, cheetah, run 3
... how the brain controls breathing is fundamental to the ... an automatic rhythmic process that persists without conscious effort ... that has intrigued many scientists for well over 100 ... rhythm throughout life? , Experimental Physiology editor Julian Paton ...
... sudden changes in water quality, creation of coastal "dead ... climate are just some of the potential consequences of ... new United Nations-backed report launched today. , Humans have ... 50 years than in any other period, some 60 ...
... can survive an otherwise lethal dose of vaccinia virus, ... the National Institute of Allergy and Infectious Diseases (NIAID), ... say the investigators, suggest that Gleevec or similar drugs ... smallpox vaccine. The classic smallpox vaccine is made from ...
Cached Biology News:How exactly does the brain control breathing? 2UN: World in big ecological mess 2UN: World in big ecological mess 3Cancer drug slows poxvirus in mice 2Cancer drug slows poxvirus in mice 3
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Biology Products: